A. E. Emery, The muscular dystrophies, Lancet, vol.359, pp.687-95, 2002.

W. D. Coley, L. Bogdanik, M. C. Vila, Y. Q. Van-der-meulen, J. H. Rayavarapu et al., Effect of genetic background on the dystrophic phenotype in mdx mice, Hum Mol Genet, vol.25, pp.130-175, 2016.

J. S. Chamberlain, J. Metzger, M. Reyes, D. Townsend, and J. A. Faulkner, Dystrophindeficient mdx mice display a reduced life span and are susceptible to spontaneous rhabdomyosarcoma, FASEB J, vol.21, pp.2195-204, 2007.

T. Larcher, A. Lafoux, L. Tesson, R. S. Thepenier, V. Francois et al., Characterization of dystrophin deficient rats: a new model for Duchenne muscular dystrophy, PLoS ONE, vol.9, p.110371, 2014.
URL : https://hal.archives-ouvertes.fr/hal-01190124

A. S. Robertson, M. J. Majchrzak, C. M. Smith, R. C. Gagnon, N. Devidze et al., Dramatic elevation in urinary amino terminal titin fragment excretion quantified by immunoassay in Duchenne muscular dystrophy patients and in dystrophin deficient rodents, Neuromuscul Disord, vol.27, pp.635-680, 2017.

A. S. Rosenberg, M. Puig, K. Nagaraju, E. P. Hoffman, S. A. Villalta et al., Immune-mediated pathology in Duchenne muscular dystrophy, Sci Transl Med, vol.7, pp.299-294, 2015.

B. A. Alman, Duchenne muscular dystrophy and steroids: pharmacologic treatment in the absence of effective gene therapy, J Pediatr Orthop, vol.25, pp.554-560, 2005.

D. Gloss, R. T. Moxley, . Iii, S. Ashwal, and M. Oskoui, Practice guideline update summary: corticosteroid treatment of Duchenne muscular dystrophy: report of the Guideline Development Subcommittee of the American Academy of Neurology, Neurology, vol.86, pp.465-72, 2016.

J. R. Mendell, K. Campbell, L. Rodino-klapac, Z. Sahenk, C. Shilling et al., Dystrophin immunity in Duchenne's muscular dystrophy, N Engl J Med, vol.363, pp.1429-1466, 2010.

E. Gussoni, G. K. Pavlath, R. G. Miller, M. A. Panzara, M. Powell et al., Specific T cell receptor gene rearrangements at the site of muscle degeneration in Duchenne muscular dystrophy, J Immunol, vol.153, pp.4798-805, 1994.

K. M. Flanigan, K. Campbell, L. Viollet, W. Wang, A. M. Gomez et al., Anti-dystrophin T cell responses in Duchenne muscular dystrophy: prevalence and a glucocorticoid treatment effect, Hum Gene Ther, vol.24, pp.797-806, 2013.

D. Burzyn, W. Kuswanto, D. Kolodin, J. L. Shadrach, M. Cerletti et al., A special population of regulatory T cells potentiates muscle repair, Cell, vol.155, pp.1282-95, 2013.

S. A. Villalta, W. Rosenthal, L. Martinez, A. Kaur, T. Sparwasser et al., Regulatory T cells suppress muscle inflammation and injury in muscular dystrophy, Sci Transl Med, vol.6, pp.258-142, 2014.

S. Bezie, D. Meistermann, L. Boucault, S. Kilens, J. Zoppi et al., Ex vivo expanded human non-cytotoxic CD8(+)CD45RC(low/-) tregs efficiently delay skin graft rejection and GVHD in humanized mice, Front Immunol, vol.8, 2014.

E. Picarda, S. Bezie, L. Boucault, E. Autrusseau, S. Kilens et al., Transient antibody targeting of CD45RC induces transplant tolerance and potent antigen-specific regulatory T cells, JCI Insight, vol.2, p.90088, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01833115

S. Menoret, S. Fontaniere, D. Jantz, L. Tesson, R. Thinard et al., Generation of Rag1-knockout immunodeficient rats and mice using engineered meganucleases, FASEB J, vol.27, pp.703-714, 2013.

S. Bezie, E. Picarda, L. Tesson, K. Renaudin, J. Durand et al., Fibrinogen-like protein 2/fibroleukin induces long-term allograft survival in a rat model through regulatory B cells, PLoS ONE, vol.10, p.119686, 2015.
URL : https://hal.archives-ouvertes.fr/inserm-02149009

I. Fisher, D. Abraham, K. Bouri, E. P. Hoffman, F. Muntoni et al., Prednisolone-induced changes in dystrophic skeletal muscle, FASEB J, vol.19, pp.834-840, 2005.

E. Matthews, R. Brassington, T. Kuntzer, F. Jichi, and A. Y. Manzur, Corticosteroids for the treatment of Duchenne muscular dystrophy, Cochrane Database Syst Rev, vol.5, p.3725, 2016.

A. M. De-luca, Use of Grip Strength Meter to Assess the Limb Strength of mdx Mice, SOP, vol.22001, 2008.

A. Lafoux, C. Baudry, C. Bonhomme, L. Ruyet, P. Huchet et al., Soluble milk protein supplementation with moderate physical activity improves locomotion function in aging rats, PLoS ONE, vol.11, p.167707, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01831752

J. Zschuntzsch, Y. Zhang, F. Klinker, G. Makosch, L. Klinge et al., Treatment with human immunoglobulin G improves the early disease course in a mouse model of Duchenne muscular dystrophy, J Neurochem, vol.136, pp.351-62, 2016.

M. D. Grounds and J. Torrisi, Anti-TNFalpha (Remicade) therapy protects dystrophic skeletal muscle from necrosis, FASEB J, vol.18, pp.676-82, 2004.

L. Pelosi, M. G. Berardinelli, D. Pasquale, L. Nicoletti, C. et al., Functional and morphological improvement of Dystrophic muscle by interleukin 6 receptor blockade, EBioMedicine, vol.2, pp.285-93, 2015.

K. Swiderski, M. Todorov, S. M. Gehrig, T. Naim, A. Chee et al., Tranilast administration reduces fibrosis and improves fatigue resistance in muscles of mdx dystrophic mice, Fibrogenesis Tissue Repair, vol.7, p.1, 2014.

C. C. Sun, S. J. Li, C. L. Yang, R. L. Xue, Y. Y. Xi et al., Sulforaphane attenuates muscle inflammation in Dystrophin-deficient mdx mice via NF-E2-related factor 2 (Nrf2)-mediated Inhibition of NF-kappaB signaling pathway, J Biol Chem, vol.290, pp.17784-95, 2015.

B. Klimek, M. E. Sali, A. Rayavarapu, S. Van-der-meulen, J. H. Nagaraju et al., Effect of the IL-1 receptor antagonist kineret(R) on disease phenotype in mdx mice, PLoS ONE, vol.11, 2016.

N. P. Evans, S. A. Misyak, J. L. Robertson, J. Bassaganya-riera, and R. W. Grange, Immune-mediated mechanisms potentially regulate the disease time-course of duchenne muscular dystrophy and provide targets for therapeutic intervention, PM R, vol.1, pp.755-68, 2009.

M. Bleakley, S. Heimfeld, K. R. Loeb, L. A. Jones, C. Chaney et al., Outcomes of acute leukemia patients transplanted with naive T cell-depleted stem cell grafts, J Clin Invest, vol.125, pp.2677-89, 2015.

F. Andreetta, P. Bernasconi, F. Baggi, P. Ferro, L. Oliva et al., Immunomodulation of TGF-beta 1 in mdx mouse inhibits connective tissue proliferation in diaphragm but increases inflammatory response: implications for antifibrotic therapy, J Neuroimmunol, vol.175, pp.77-86, 2006.

S. Bezie, I. Anegon, and C. Guillonneau, Advances on CD8+ Tregs and their potential in transplantation, Transplantation, vol.102, pp.1467-78, 2018.

D. Kolodin, N. Van-panhuys, C. Li, A. M. Magnuson, D. Cipolletta et al., Antigen-and cytokine-driven accumulation of regulatory T cells in visceral adipose tissue of lean mice, Cell Metab, vol.21, pp.543-57, 2015.

C. R. Heier, J. M. Damsker, Q. Yu, B. C. Dillingham, T. Huynh et al., VBP15, a novel anti-inflammatory and membrane-stabilizer, improves muscular dystrophy without side effects, EMBO Mol Med, vol.5, pp.1569-85, 2013.

L. S. Conklin, J. M. Damsker, E. P. Hoffman, W. J. Jusko, P. D. Mavroudis et al., Phase IIa trial in Duchenne muscular dystrophy shows vamorolone is a first-in-class dissociative steroidal anti-inflammatory drug, Pharmacol Res, vol.136, pp.140-50, 2018.

S. Gregori, P. Mangia, R. Bacchetta, E. Tresoldi, F. Kolbinger et al., An anti-CD45RO/RB monoclonal antibody modulates T cell responses via induction of apoptosis and generation of regulatory T cells, J Exp Med, vol.201, pp.1293-305, 2005.

A. I. Lazarovits, S. Poppema, Z. Zhang, M. Khandaker, L. Feuvre et al., Prevention and reversal of renal allograft rejection by antibody against CD45RB, Nature, vol.380, pp.717-737, 1996.

M. J. Spencer, E. Montecino-rodriguez, K. Dorshkind, and J. G. Tidball, Helper (CD4(+)) and cytotoxic (CD8(+)) T cells promote the pathology of dystrophin-deficient muscle, Clin Immunol, vol.98, pp.235-278, 2001.

L. Ouisse, R. S. Lafoux, A. Larcher, T. Tesson, L. Chenouard et al., Immunological characterization of a rat model of Duchenne's disease and demonstration of improved muscle strength after anti-CD45RC antibody treatment, bioRxiv, p.407023, 2018.
URL : https://hal.archives-ouvertes.fr/hal-02509540